{{medical}}
{{Infobox medical intervention
|name=癌症免疫疗法|synonym=|image=Peptide bound to Rituximab FAB.png|caption=CD20的[[肽|肽]][[抗原表位|抗原表位]]与[[利妥昔单抗|利妥昔单抗]]的抗原结合段（Fab）相结合|alt=|pronounce=|specialty=<!-- from Wikidata, can be overwritten -->|synonyms=|ICD10=|ICD9=|ICD9unlinked=|CPT=|MeshID=|LOINC=|other_codes=|MedlinePlus=|eMedicine=}}
'''癌症免疫疗法'''（{{lang-en|cancer immunotherapy}}或{{lang|en|immuno-oncology}}）是一类通过激活[[免疫系统|免疫系统]]来治疗[[癌症|癌症]]的方法。此类疗法采用了{{le|癌症免疫学|Cancer immunology}}研究的成果，这是[[肿瘤学|肿瘤学]]中一个快速发展的研究方向。肿瘤细胞表面有能被免疫系统识别的肿瘤[[抗原|抗原]]，而这正是癌症免疫的基础。这些抗原一般为[[蛋白质|蛋白质]]或高分子（如[[碳水化合物|碳水化合物]]）。[[免疫疗法|免疫疗法]]可分为主动免疫、被动免疫与联合免疫。主动免疫疗法直接诱导自身免疫系统，使其能够识别肿瘤抗原，进而攻击肿瘤细胞。而被动免疫疗法则是借助外源物质发挥抗肿瘤作用，其中会用到[[单克隆抗体|单克隆抗体]]（简称单抗）、[[淋巴细胞|淋巴细胞]]、[[细胞因子|细胞因子]]等。

在这些疗法中，已有一些抗体疗法被批准用于治疗多种类型的癌症。<ref>{{cite journal | vauthors = Korneev KV, Atretkhany KN, Drutskaya MS, Grivennikov SI, Kuprash DV, Nedospasov SA | title = TLR-signaling and proinflammatory cytokines as drivers of tumorigenesis | journal = Cytokine | volume = 89 | pages = 127–135 | date = January 2017 | pmid = 26854213 | doi = 10.1016/j.cyto.2016.01.021 }}</ref>抗体是一类由免疫系统产生的蛋白质，用于与细胞表面的靶抗原结合。免疫系统通常用其来攻击[[病原体|病原体]]。每种抗体对一种或数种蛋白质有特异性，那些能与肿瘤抗原结合的抗体可用于治疗癌症。[[细胞表面受体|细胞表面受体]]是抗体疗法的主要目标，如{{le|CD20}}、[[细胞程式死亡-配体1|CD274]]与{{le|CD279|Programmed cell death protein 1}}等。一旦与肿瘤抗原相结合，抗体可以引发[[ADCC作用|抗体依赖细胞介导的细胞毒作用]]（ADCC）、激活[[补体系统|补体系统]]或阻断受体与其[[配体_(生物化学)|配体]]的相互作用，最终导致细胞死亡。目前已被批准的抗体包括{{le|阿仑单抗|Alemtuzumab}}、{{le|伊匹单抗|Ipilimumab}}、{{le|纳武单抗|Nivolumab}}、{{le|奥法木单抗|Ofatumumab}}与[[利妥昔单抗|利妥昔单抗]]等。

主动细胞疗法一般则会从血液或肿瘤中分离出免疫细胞，在将这些细胞体外培养后再输回患者体内去攻击肿瘤。此外，也可以经由[[基因工程|基因工程]]改造后使免疫细胞表达肿瘤特异性受体，再经培养后输回患者体内。能运用于此种疗法的细胞包括[[自然杀伤细胞|自然杀伤细胞]]（简称NK细胞）、{{le|淋巴因子激活的杀伤细胞|Lymphokine-activated killer cell}}（简称LAK细胞）、[[细胞毒性T细胞|细胞毒性T细胞]]（简称CTL细胞）、[[树突状细胞|树突状细胞]]（简称DC细胞）等。

== 细胞免疫疗法 ==
=== 树突状细胞疗法 ===
[[File:Dendritic_cell_therapy.png|thumb]]
树突状细胞（DC细胞）能获取肿瘤抗原的特征信息后呈递给淋巴细胞，这些细胞在被激活后会攻击肿瘤细胞、引发抗肿瘤免疫应答。DC细胞是哺乳动物免疫系统中的一种[[抗原提呈细胞|抗原提呈细胞]]（APC）<ref name="pmid11481463">{{cite journal | vauthors = Riddell SR | title = Progress in cancer vaccines by enhanced self-presentation | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 98 | issue = 16 | pages = 8933–5 | date = July 2001 | pmid = 11481463 | pmc = 55350 | doi = 10.1073/pnas.171326398 | bibcode = 2001PNAS...98.8933R }}</ref>，在癌症治疗中用于识别肿瘤抗原。<ref name="pmid23890062">{{cite journal | vauthors = Palucka K, Banchereau J | title = Dendritic-cell-based therapeutic cancer vaccines | journal = Immunity | volume = 39 | issue = 1 | pages = 38–48 | date = July 2013 | pmid = 23890062 | pmc = 3788678 | doi = 10.1016/j.immuni.2013.07.004 }}</ref>{{link-en|Sipuleucel-T|Sipuleucel-T}}是首个经批准的基于DC细胞的癌症疗法。

一种促使DC细胞提呈肿瘤抗原信息的方法是使用自体肿瘤细胞溶解物或短肽致敏。<ref name="pmid27235694">{{cite journal | vauthors = Hirayama M, Nishimura Y | title = The present status and future prospects of peptide-based cancer vaccines | journal = [[International_Immunology|International Immunology]] | volume = 28 | issue = 7 | pages = 319–28 | date = July 2016 | pmid = 27235694 | doi = 10.1093/intimm/dxw027 }}</ref>这些抗原肽常与具有强免疫原性的{{le|佐剂|Adjuvant}}一同使用，用于增强抗肿瘤免疫应答。其他佐剂还包括能吸引、激活DC细胞的蛋白质或其他化学物质，比如{{le|粒细胞-巨噬细胞集落刺激因子|Granulocyte-macrophage colony-stimulating factor}}（GM-CSF）。

让肿瘤细胞表达GM-CSF可以在体内激活DC细胞，如运用基因工程手段改造肿瘤细胞使其产生GM-CSF，或用能表达GM-CSF的{{le|溶瘤病毒|Oncolytic virus}}感染肿瘤细胞。

此外，亦可从患者血液中分离DC细胞后在体外将其激化。单个肿瘤特异性肽/蛋白质或者肿瘤细胞溶解物可用来活化DC细胞。之后再将这些细胞（或加上佐剂）输回患者体内，以期引发免疫应答。

DC细胞疗法还包括使用能与DC细胞表面受体结合的抗体。将抗原加到抗体上能够诱导DC细胞成熟，进而诱发肿瘤免疫应答。{{le|TLR3}}、{{le|TLR7}}、{{le|TLR8}}、{{le|CD40|
CD40 (protein)}}等DC细胞受体都被用作抗体目标。<ref name="pmid23890062" />

==== 批准药物 ====
2010年，Sipuleucel-T（商品名Provenge，普列威）被批准用于治疗无症状或仅有轻微症状的转移性去势抵抗性[[前列腺癌|前列腺癌]]。该疗法首先采用{{le|白细胞分离术|Leukapheresis}}将患者血液中的APC分离出来，再同由GM-CSF和{{le|前列腺酸性磷酸酶|Prostatic acid phosphatase}}（PAP）制成的{{le|融合蛋白|Fusion protein}}PA2024共同培养后输回患者体内。如此重复三次为一个完整疗程。<ref>{{cite journal | vauthors = Gardner TA, Elzey BD, Hahn NM | title = Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer | journal = Human Vaccines & Immunotherapeutics | volume = 8 | issue = 4 | pages = 534–9 | date = April 2012 | pmid = 22832254 | doi = 10.4161/hv.19795 }}</ref><ref>{{cite journal | vauthors = Oudard S | title = Progress in emerging therapies for advanced prostate cancer | journal = Cancer Treatment Reviews | volume = 39 | issue = 3 | pages = 275–89 | date = May 2013 | pmid = 23107383 | doi = 10.1016/j.ctrv.2012.09.005 }}</ref><ref>{{cite journal | vauthors = Sims RB | title = Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer | journal = Vaccine | volume = 30 | issue = 29 | pages = 4394–7 | date = June 2012 | pmid = 22122856 | doi = 10.1016/j.vaccine.2011.11.058 }}</ref><ref>{{cite journal | vauthors = Shore ND, Mantz CA, Dosoretz DE, Fernandez E, Myslicki FA, McCoy C, Finkelstein SE, Fishman MN | title = Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer | journal = Cancer Control | volume = 20 | issue = 1 | pages = 7–16 | date = January 2013 | pmid = 23302902 | doi = 10.1177/107327481302000103 }}</ref>

=== CAR-T细胞疗法 ===
嵌合抗原受体T细胞（CAR-T）免疫疗法通过改造[[T细胞|T细胞]]以使其能更有效地识别并杀伤肿瘤细胞。从患者体内采集T细胞后，在其中加上能够识别肿瘤细胞的{{le|嵌合抗原受体|Chimeric antigen receptor}}（CAR），再将融合后的CAR-T细胞输回患者体内以攻击肿瘤。

==== 批准药物 ====
2017年，[[美国食品药品监督管理局|美国食品药品监督管理局]]（FDA）批准了用于治疗[[急性淋巴性白血病|急性淋巴性白血病]]（ALL）的CAR-T疗法{{le|Tisagenlecleucel}}（商品名Kymriah）。<ref>{{Cite web|url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm|title=Press Announcements - FDA approval brings first gene therapy to the United States|last=Commissioner|first=Office of the|website=www.fda.gov|language=en|access-date=2017-12-13|archive-url=https://web.archive.org/web/20170903080825/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm|archive-date=2017-09-03|dead-url=no}}</ref>该疗法能够杀死体内的{{le|CD19}}阳性细胞（B细胞），不过除了癌细胞外，也会杀死正常的抗体生成细胞。

{{le|Axicabtagene ciloleucel}}（商品名Yescarta）则是另一种CAR-T免疫疗法，于2017年被批准用于治疗[[弥漫大B细胞淋巴瘤|弥漫大B细胞淋巴瘤]]。<ref name="fda.gov">{{cite web|url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm581216.htm|title=FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma|publisher=fda.gov|date=2017-10-18|accessdate=2017-11-08|archive-url=https://web.archive.org/web/20171108015015/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm581216.htm|archive-date=2017-11-08|dead-url=no}}</ref>

== 抗体疗法 ==
[[File:Engineered_monoclonal_antibodies.svg|thumb]]
[[抗体|抗体]]是[[后天免疫系统|获得性免疫应答]]的关键，在识别外源抗原与激发免疫应答的过程中至关重要。抗体是一些由[[B细胞|B细胞]]分泌的Y形蛋白质，由两个片段组成：一是用于结合抗原的{{le|抗原结合段|Fragment antigen-binding}}（Fab段），二是能够与[[巨噬细胞|巨噬细胞]]、[[中性粒细胞|中性粒细胞]]、NK细胞等免疫细胞表面的{{le|Fc受体|Fc receptor}}相互作用的{{le|可结晶段|Fragment crystallizable region}}（Fc段）。许多免疫治疗方案中都会用到抗体。应用单抗技术能够制造出针对特定肿瘤抗原的抗体。

=== 抗体类型 ===
==== 偶联 ====
运用于癌症治疗的抗体可分为两类：<ref name="pmid22437872" />

* 裸单克隆抗体是指没有附加药物的抗体，大多数抗体疗法中采用的即是此类抗体。
* 偶联单克隆抗体则是将抗体与其他具有细胞毒性或[[放射性|放射性]]的分子连接在一起。用来连接的化学物质一般为[[化疗|化疗]]药物，不过有时亦会采用其他毒素。抗体与肿瘤细胞表面的特定抗原结合，从而将药物投递至肿瘤。与放射性化合物相结合的抗体称为放射性标记（radiolabelled）抗体。而同化疗药物与毒素连接的则分别被称为化疗标记（chemolabelled）抗体与免疫毒素（immunotoxin）。<ref name=":0" />

==== Fc段 ====
Fc段能与Fc受体结合的特征对于抗体激发免疫系统而言十分重要。Fc段有不同的亚类，并且可以经由[[糖基化|糖基化]]等过程进行修饰改造。Fc段的变化会影响抗体与Fc受体结合的能力，并决定抗体所引发的免疫应答类型。<ref>{{cite journal | vauthors = Pincetic A, Bournazos S, DiLillo DJ, Maamary J, Wang TT, Dahan R, Fiebiger BM, Ravetch JV | title = Type I and type II Fc receptors regulate innate and adaptive immunity | journal = Nature Immunology | volume = 15 | issue = 8 | pages = 707–16 | date = August 2014 | pmid = 25045879 | doi = 10.1038/ni.2939 }}</ref>包括{{le|细胞程序性死亡受体1|Programmed cell death protein 1
}}（PD-1）抑制剂与[[细胞程序性死亡配体1|细胞程序性死亡配体1]]（PD-L1）抑制剂在内的许多癌症免疫治疗药物都是抗体。比如抗PD-1的{{le|免疫检查点|Immune checkpoint}}阻断药可以与T细胞上表达的PD-1结合，从而激活T细胞以清除肿瘤。<ref>{{cite journal | vauthors = Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M | title = Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | journal = The New England Journal of Medicine | volume = 366 | issue = 26 | pages = 2443–54 | date = June 2012 | pmid = 22658127 | pmc = 3544539 | doi = 10.1056/NEJMoa1200690 }}</ref>除了与PD-1结合的Fab段外，抗PD-1药物也有Fc段。实验表明免疫药物的Fc段能够影响疗效。例如，抗PD-1药物的Fc段如果与抑制性Fc受体结合会对疗效有负面影响。<ref>{{cite journal | vauthors = Dahan R, Sega E, Engelhardt J, Selby M, Korman AJ, Ravetch JV | title = FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis | journal = Cancer Cell | volume = 28 | issue = 4 | pages = 543 | date = October 2015 | pmid = 28854351 | doi = 10.1016/j.ccell.2015.09.011 }}</ref>影像研究进一步表明抗PD-1药物的Fc段可能与肿瘤相关巨噬细胞表达的Fc受体结合，导致药物从其目标的T细胞上被夺去，限制了治疗效果。<ref>{{cite journal | vauthors = Arlauckas SP, Garris CS, Kohler RH, Kitaoka M, Cuccarese MF, Yang KS, Miller MA, Carlson JC, Freeman GJ, Anthony RM, Weissleder R, Pittet MJ | title = In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy | journal = Science Translational Medicine | volume = 9 | issue = 389 | pages = eaal3604 | date = May 2017 | pmid = 28490665 | pmc = 5734617 | doi = 10.1126/scitranslmed.aal3604 }}</ref>此外，以共刺激蛋白CD40为靶点的抗体需要与特定的Fc受体作用以达到最佳效果。<ref>{{cite journal | vauthors = Dahan R, Barnhart BC, Li F, Yamniuk AP, Korman AJ, Ravetch JV | title = Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement | journal = Cancer Cell | volume = 29 | issue = 6 | pages = 820–831 | date = July 2016 | pmid = 27265505 | pmc = 4975533 | doi = 10.1016/j.ccell.2016.05.001 }}</ref>这些研究说明了基于抗体的免疫检查点阻断疗法中Fc段的重要性。

==== 非人源/人源抗体 ====
抗体还可分为鼠源抗体、人鼠嵌合抗体、人源化抗体与人源抗体。鼠源抗体并非来自人类，因而有产生免疫反应的风险。人鼠嵌合抗体用人类抗体中的恒定区（constant region）替换鼠源抗体的对应区域，试图减轻鼠源抗体的[[免疫原性|免疫原性]]。人源化坑体的绝大部分都来自人类，仅有可变区（variable region）中的[[互补性决定区|互补性决定区]]为鼠源。人源坑体则完全由人类DNA制成。<ref name=":0">{{cite journal | vauthors = Harding FA, Stickler MM, Razo J, DuBridge RB | title = The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions | journal = MAbs | volume = 2 | issue = 3 | pages = 256–65 | date = May–Jun 2010 | pmid = 20400861 | pmc = 2881252 | doi = 10.4161/mabs.2.3.11641 }}</ref>

[[File:Antibody-dependent_cell-mediated_cytotoxicity.png|left]]
=== 细胞死亡机制 ===
==== 抗体依赖细胞介导的细胞毒性（ADCC）====
[[ADCC作用|抗体依赖细胞介导的细胞毒性]]（ADCC）作用需要抗体与靶细胞的表面结合。抗体由Fab段与Fc段构成，而免疫细胞可以通过其Fc受体识别抗体的Fc段。在NK细胞等许多免疫细胞中都有Fc受体。当NK细胞与被抗体覆盖的靶细胞相遇时，前者的Fc受体与后者的Fc段相互作用，进而释放[[穿孔素|穿孔素]]与{{le|颗粒酶B|Granzyme B}}以杀伤肿瘤细胞。[[利妥昔单抗|利妥昔单抗]]、{{le|奥法木单抗|Ofatumumab}}与{{le|阿仑单抗|Alemtuzumab}}皆采用ADCC机制。有研究试图改造抗体的Fc段，此举能提高其与一种名为FcγRIIIA的特定Fc受体的亲和力，以期显著提升疗效。<ref>{{cite journal | vauthors = Weiner LM, Surana R, Wang S | title = Monoclonal antibodies: versatile platforms for cancer immunotherapy | journal = Nature Reviews. Immunology | volume = 10 | issue = 5 | pages = 317–27 | date = May 2010 | pmid = 20414205 | pmc = 3508064 | doi = 10.1038/nri2744 }}</ref><ref>{{cite journal | vauthors = Seidel UJ, Schlegel P, Lang P | title = Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies | journal = Frontiers in Immunology | volume = 4 | pages = 76 | year = 2013 | pmid = 23543707 | pmc = 3608903 | doi = 10.3389/fimmu.2013.00076 }}</ref>

==== 补体 ====
当抗体与细胞表面结合、补体途径被激活后，[[补体系统|补体系统]]中的血液蛋白可致使细胞死亡。这套系统平时用于清除外来病菌，但也可以被癌症治疗中的抗体所激活。无论是人鼠嵌合抗体、人源化抗体还是人源抗体都能激活该系统，只要其中包含[[IgG|IgG1]]的Fc段。补体激活杀死细胞的机制包括补体依赖的细胞毒性（形成[[补体系统膜攻击复合物|膜攻击复合物]]）、增强ADCC作用以及CR3依赖细胞介导的细胞毒性。其中补体依赖的细胞毒性（complement-dependent cytotoxicity，CDC）在抗体与肿瘤细胞表面结合时发生，C1复合物与抗体结合后被激活，最终在肿瘤[[细胞膜|细胞膜]]上形成穿膜孔道。<ref>{{cite journal | vauthors = Gelderman KA, Tomlinson S, Ross GD, Gorter A | title = Complement function in mAb-mediated cancer immunotherapy | journal = Trends in Immunology | volume = 25 | issue = 3 | pages = 158–64 | date = March 2004 | pmid = 15036044 | doi = 10.1016/j.it.2004.01.008 }}</ref>

=== FDA批准的抗体 ===
{| class="wikitable" style="margin: 1em auto 1em auto" width="600px" align="right" href="Alemtuzumab"
|+ '''癌症免疫疗法：单克隆抗体'''<ref name="pmid22437872">{{cite journal | vauthors = Scott AM, Wolchok JD, Old LJ | title = Antibody therapy of cancer | journal = Nature Reviews. Cancer | volume = 12 | issue = 4 | pages = 278–87 | date = March 2012 | pmid = 22437872 | doi = 10.1038/nrc3236 }}</ref><ref name="Waldmann">{{cite journal | vauthors = Waldmann TA | title = Immunotherapy: past, present and future | journal = Nature Medicine | volume = 9 | issue = 3 | pages = 269–77 | date = March 2003 | pmid = 12612576 | doi = 10.1038/nm0303-269 }}</ref>
! style="width: 15%" | 抗体
! style="width: 15%" | 英文名
! style="width: 15%" | 商品名
! style="width: 15%" | 类型 
! style="width: 10%" | 靶点
! style="width: 10%" | 批准日期
! style="width: 20%" | 批准疾病治疗
|-
| 阿仑单抗
| Alemtuzumab
| Campath
| 人源化
| CD52|| 2001年 || [[B细胞慢性淋巴细胞白血病|B细胞慢性淋巴细胞白血病]]<ref>{{cite journal | vauthors = Demko S, Summers J, Keegan P, Pazdur R | title = FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia | journal = The Oncologist | volume = 13 | issue = 2 | pages = 167–74 | date = February 2008 | pmid = 18305062 | doi = 10.1634/theoncologist.2007-0218 }}</ref>

|-
| 阿特珠单抗 
| Atezolizumab
| Tecentriq
| 人源化
| PD-L1
| 2016年
| [[膀胱癌|膀胱癌]]<ref name="FDA-BC-2016">{{cite news|url=http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm501762.htm|title=FDA approves new, targeted treatment for bladder cancer|date=2016-05-18|publisher=FDA|access-date=2016-05-20|archive-url=https://web.archive.org/web/20180424213005/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm501762.htm|archive-date=2018-04-24|dead-url=no}}</ref>
|-
| 阿维单抗
| Avelumab
| Bavencio
| 人源
| PD-L1
| 2017年
| 转移性{{le|梅克尔细胞瘤|Merkel-cell carcinoma}}<ref>{{Cite web|url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761049s000lbl.pdf|title=US Food and Drug Administration - Avelumab Prescribing Label|last=|first=|date=|website=|archive-url=https://web.archive.org/web/20170324090609/http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761049s000lbl.pdf|archive-date=2017-03-24|dead-url=no|access-date=}}</ref>
|-
| 伊匹单抗
| Ipilimumab 
| Yervoy 
| 人源
| CTLA-4
| 2011年
| 转移性[[黑色素瘤|黑色素瘤]]<ref>{{cite web|last=Pazdur|first=Richard|name-list-format=vanc|title=FDA approval for Ipilimumab|url=http://www.cancer.gov/cancertopics/druginfo/fda-ipilimumab|accessdate=2013-11-07|archive-url=https://web.archive.org/web/20150406011836/http://www.cancer.gov/cancertopics/druginfo/fda-ipilimumab|archive-date=2015-04-06|dead-url=no}}</ref>
|-
| 奥法木单抗
| Ofatumumab
| Arzerra 
| 人源
| CD20
| 2009年
| 顽固性[[慢性淋巴细胞白血病|慢性淋巴细胞白血病]]<ref>{{cite journal | vauthors = Lemery SJ, Zhang J, Rothmann MD, Yang J, Earp J, Zhao H, McDougal A, Pilaro A, Chiang R, Gootenberg JE, Keegan P, Pazdur R | title = U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab | journal = Clinical Cancer Research | volume = 16 | issue = 17 | pages = 4331–8 | date = September 2010 | pmid = 20601446 | doi = 10.1158/1078-0432.CCR-10-0570 }}</ref>
|-
| 纳武单抗
| Nivolumab
| Opdivo
| 人源
| PD-1
| 2014年
| 不可切除或转移性黑色素瘤、鳞状{{le|非小细胞肺癌|Non-small cell lung cancer}}、{{le|肾细胞癌|Renal cell carcinoma}}、[[大肠癌|大肠癌]]、[[肝细胞癌|肝细胞癌]]、[[霍奇金氏淋巴瘤|典型霍奇金氏淋巴瘤]]<ref name="sa15">{{cite journal | vauthors = Sharma P, Allison JP | title = The future of immune checkpoint therapy | journal = Science | volume = 348 | issue = 6230 | pages = 56–61 | date = April 2015 | pmid = 25838373 | doi = 10.1126/science.aaa8172 | bibcode = 2015Sci...348...56S }}</ref><ref>{{cite web|url=https://www.drugs.com/history/opdivo.html|title=Opdivo Drug Approval History|access-date=2018-10-04|archive-url=https://web.archive.org/web/20171229172200/https://www.drugs.com/history/opdivo.html|archive-date=2017-12-29|dead-url=no}}</ref>
|-
| 帕姆单抗
| Pembrolizumab
| Keytruda
| 人源化
| PD-1
| 2014年
| 转移性黑色素瘤<ref name="sa15" />
|-
| [[利妥昔单抗|利妥昔单抗]]
| Rituximab
| Rituxan、Mabthera 
| 人鼠嵌合 
| CD20 
| 1997年
|[[非霍奇金氏淋巴瘤|非霍奇金氏淋巴瘤]]<ref>{{cite journal | vauthors = James JS, Dubs G | title = FDA approves new kind of lymphoma treatment. Food and Drug Administration | journal = AIDS Treatment News | issue =  284 | pages = 2–3 | date = December 1997 | pmid = 11364912 }}</ref>
|- 
| 度伐鲁单抗
| Durvalumab
| Imfinzi
| 人源
| PD-L1
| 2017年
| 膀胱癌<ref>{{Cite web|title=Approved Drugs - Durvalumab (Imfinzi)|url=https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm555930.htm|last=Research|first=Center for Drug Evaluation and|website=www.fda.gov|language=en|access-date=2017-05-06|archive-url=https://web.archive.org/web/20170508150028/https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555930.htm|archive-date=2017-05-08|dead-url=no}}</ref>、非小细胞肺癌<ref>{{Cite web|url=https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm597248.htm|title=FDA approves durvalumab after chemoradiation for unresectable stage III NSCLC|last=|first=|date=|website=|archive-url=https://web.archive.org/web/20180725215342/https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm597248.htm|archive-date=2018-07-25|dead-url=no|access-date=}}</ref>
|-
|}

==== 阿仑单抗 ====
阿仑单抗（alemtuzuma，商品名Campath-1H）是一种抗{{le|CD52}}的人源化IgG1单抗，用于医治{{le|氟达拉滨|Fludarabine}}治疗无效的[[慢性淋巴细胞白血病|慢性淋巴细胞白血病]]、{{le|皮肤T细胞淋巴瘤|Cutaneous T cell lymphoma}}、{{le|外周T细胞淋巴瘤|Peripheral T-cell lymphoma}}与{{le|T细胞幼淋巴细胞白血病|T-cell prolymphocytic leukemia}}。超过95%的外周血[[淋巴细胞|淋巴细胞]]（包括T细胞和B细胞）与[[单核细胞|单核细胞]]表面存在CD52，但其在淋巴细胞中的作用未知。阿仑单抗能与CD52结合，经补体结合与ADCC机制引发细胞毒性作用。由于靶细胞为免疫细胞，在使用阿仑单抗治疗时可能会有感染、中毒、[[骨髓抑制|骨髓抑制]]等副作用。<ref>Byrd JC, Stilgenbauer S, Flinn IW. [http://www.asheducationbook.org/cgi/content/full/2004/1/163 Chronic Lymphocytic Leukemia.] {{Wayback|url=http://www.asheducationbook.org/cgi/content/full/2004/1/163 |date=20061202082829 }} Hematology (Am Soc Hematol Educ Program) 2004: 163-183. Date retrieved: 26/01/2006.</ref><ref>{{cite journal | vauthors = Domagała A, Kurpisz M | title = CD52 antigen--a review | journal = Medical Science Monitor | volume = 7 | issue = 2 | pages = 325–31 | date = Mar–Apr 2001 | pmid = 11257744 }}</ref><ref>{{cite journal | vauthors = Dearden C | title = How I treat prolymphocytic leukemia | journal = Blood | volume = 120 | issue = 3 | pages = 538–51 | date = July 2012 | pmid = 22649104 | doi = 10.1182/blood-2012-01-380139 }}</ref>

==== 阿特珠单抗 ====
阿特珠单抗（atezolizumab，商品名Tecentriq）是一种抗PD-L1的全人源化IgG1单抗，用于治疗非小细胞肺癌、尿路上皮癌等。

==== 度伐鲁单抗 ====
度伐鲁单抗（durvalumab，商品名Imfinzi）是一种人源IgG1κ单抗，可阻断PD-L1和PD-1、CD80（B7.1）之间的相互作用。度伐鲁单抗被批准可用于治疗满足以下条件的局部晚期或转移性尿路上皮癌：
* 在含铂化疗期间或之后疾病有进展；
* 在含铂化疗的新辅助治疗或辅助治疗的十二个月内疾病有进展。

==== 伊匹单抗 ====
伊匹单抗（ipilimumab，商品名Yervoy）是一种抗{{le|细胞毒性T淋巴细胞相关抗原4|CTLA-4}}（CTLA-4）的人源IgG1单抗。通常情况下，T细胞的激活依赖于两个信号：与[[主要组织相容性复合物|主要组织相容性复合物]]（MHC）抗原结合的T细胞受体，以及与蛋白{{le|CD80}}或{{le|CD86}}结合的T细胞表面受体CD28。CTLA-4能与CD80或CD86结合，阻断它们与CD28的结合，进而抑制T细胞的活化。<ref name="pmid21629286">{{cite journal | vauthors = Sondak VK, Smalley KS, Kudchadkar R, Grippon S, Kirkpatrick P | title = Ipilimumab | journal = Nature Reviews. Drug Discovery | volume = 10 | issue = 6 | pages = 411–2 | date = June 2011 | pmid = 21629286 | doi = 10.1038/nrd3463 }}</ref><ref name="pmid21900389">{{cite journal | vauthors = Lipson EJ, Drake CG | title = Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma | journal = Clinical Cancer Research | volume = 17 | issue = 22 | pages = 6958–62 | date = November 2011 | pmid = 21900389 | pmc = 3575079 | doi = 10.1158/1078-0432.CCR-11-1595 }}</ref><ref name="pmid21294471">{{cite journal | vauthors = Thumar JR, Kluger HM | title = Ipilimumab: a promising immunotherapy for melanoma | journal = Oncology | volume = 24 | issue = 14 | pages = 1280–8 | date = December 2010 | pmid = 21294471 }}</ref><ref name="pmid11244047">{{cite journal | vauthors = Chambers CA, Kuhns MS, Egen JG, Allison JP | title = CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy | journal = Annual Review of Immunology | volume = 19 | pages = 565–94 | year = 2001 | pmid = 11244047 | doi = 10.1146/annurev.immunol.19.1.565 }}</ref>

免疫系统需要活化的[[细胞毒性T细胞|细胞毒性T细胞]]去攻击[[黑色素瘤|黑色素瘤]]细胞。正常情形下被抑制的黑色素瘤特异性的活化细胞毒性T细胞可引发抗肿瘤免疫应答。伊匹单抗能够改变[[调节T细胞|调节T细胞]]与细胞毒性T细胞的比例，以强化免疫应答。调节T细胞会抑制其他T细胞，因而更多的调节T细胞不利于清除肿瘤。<ref name="pmid21629286" /><ref name="pmid21900389" /><ref name="pmid21294471" /><ref name="pmid11244047" />

==== 纳武单抗 ====
纳武单抗（nivolumab，商品名Opdivo）是一种抗PD-1的人源IgG4单抗，可用于治疗[[黑色素瘤|黑色素瘤]]、{{le|非小细胞肺癌|Non-small-cell lung carcinoma}}、{{le|肾细胞癌|Renal cell carcinoma}}等。

==== 奥法木单抗 ====
奥法木单抗（ofatumumab，商品名Arzerra）是第二代抗{{le|CD20}}的人源IgG1单抗。其可以与在B细胞中高表达的CD20结合，从而治疗[[慢性淋巴细胞白血病|慢性淋巴细胞白血病]]。奥法木单抗与CD20蛋白上的小环结合，而同样以CD20为靶点的利妥昔单抗则与CD20的大环结合。这或许可以解释两者的不同特性。与利妥昔单抗相比，奥法木单抗降低了免疫原性，在更低剂量下便能够激活CDC作用。<ref>{{cite journal | vauthors = Castillo J, Perez K | title = The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies | journal = Journal of Blood Medicine | volume = 1 | pages = 1–8 | year = 2010 | pmid = 22282677 | pmc = 3262337 | doi = 10.2147/jbm.s7284 }}</ref><ref>{{cite journal | vauthors = Zhang B | title = Ofatumumab | journal = MAbs | volume = 1 | issue = 4 | pages = 326–31 | date = Jul–Aug 2009 | pmid = 20068404 | pmc = 2726602 | doi = 10.4161/mabs.1.4.8895 }}</ref>

==== 帕姆单抗 ====
帕姆单抗（pembrolizumab，商品名Keytruda）是抗PD-1的人源化IgG4单抗，可用于治疗转移性非小细胞肺癌、不可切除或转移性黑色素瘤，并可在使用{{le|铂基类抗肿瘤药物|Platinum-based antineoplastic
}}后作为{{le|头颈部鳞状细胞癌|Head and neck squamous-cell carcinoma}}的二线治疗方案，同时亦能用于治疗成人与儿童的顽固性典型[[霍奇金氏淋巴瘤|霍奇金氏淋巴瘤]]。<ref name=USlabel2016>{{cite web|title=Pembrolizumab label|url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125514s014lbl.pdf|publisher=FDA|date=May 2017}} linked from [http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125514 Index page at FDA website] {{Wayback|url=http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125514 |date=20170714005234 }} November 2016</ref><ref name=UKlabel2016>{{cite web|title=Pembrolizumab label at eMC|url=https://www.medicines.org.uk/emc/medicine/30602|publisher=UK Electronic Medicines Compendium|date=2017-01-27|access-date=2018-10-04|archive-url=https://web.archive.org/web/20171213010050/https://www.medicines.org.uk/emc/medicine/30602|archive-date=2017-12-13|dead-url=no}}</ref>

==== 利妥昔单抗 ====
{{main|利妥昔单抗}}
利妥昔单抗（rituximab，商品名Rituxan）是一种抗CD20的人鼠嵌合IgG1单抗，由同样以CD20为靶点的{{le|替伊莫单抗|Ibritumomab}}进一步研发而来，能有效治疗特定类型的B细胞恶性肿瘤，其中包括侵袭性或惰性淋巴瘤（如[[弥漫大B细胞淋巴瘤|弥漫大B细胞淋巴瘤]]、滤泡淋巴瘤）以及[[白血病|白血病]]（如B细胞慢性淋巴细胞白血病）。尽管CD20的功能尚不明确，但可能与[[钙离子通道|钙离子通道]]有关。该单抗的作用机制为补体介导的细胞毒性（complement-mediated cytotoxicity，CMC）。其他机制还包括[[细胞凋亡|细胞凋亡]]与细胞生长阻滞。此外，利妥昔单抗还能与化疗联用，可提高肿瘤B细胞对化疗的敏感性。<ref>{{cite journal | vauthors = Keating GM | title = Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma | journal = Drugs | volume = 70 | issue = 11 | pages = 1445–76 | date = July 2010 | pmid = 20614951 | doi = 10.2165/11201110-000000000-00000 }}</ref><ref name="Plosker 2003 803–43">{{cite journal | vauthors = Plosker GL, Figgitt DP | title = Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia | journal = Drugs | volume = 63 | issue = 8 | pages = 803–43 | year = 2003 | pmid = 12662126 | doi = 10.2165/00003495-200363080-00005 }}</ref><ref name="Plosker 2003 803–43" /><ref>{{cite journal | vauthors = Cerny T, Borisch B, Introna M, Johnson P, Rose AL | title = Mechanism of action of rituximab | journal = Anti-Cancer Drugs | volume = 13 Suppl 2 | pages = S3–10 | date = November 2002 | pmid = 12710585 | doi = 10.1097/00001813-200211002-00002 }}</ref><ref name="Janeway">{{cite book |last=Janeway |first=Charles |authorlink=Charles Janeway |first2=Paul |last2=Travers |first3=Mark |last3=Walport |first4=Mark |last4=Shlomchik |name-list-format=vanc |title=Immunobiology |edition=Fifth |publisher=Garland Science |year=2001 |location=New York and London |pages= |url=https://www.ncbi.nlm.nih.gov/books/bv.fcgi?call=bv.View..ShowTOC&rid=imm.TOC&depth=10 |isbn=978-0-8153-4101-7 |access-date=2018-10-04 |archive-url=https://web.archive.org/web/20090628195820/http://www.ncbi.nlm.nih.gov/books/bv.fcgi?call=bv.View..ShowTOC&rid=imm.TOC&depth=10 |archive-date=2009-06-28 |dead-url=no }}{{page needed|date=February 2018}}</ref><ref>{{cite journal | vauthors = Weiner GJ | title = Rituximab: mechanism of action | journal = Seminars in Hematology | volume = 47 | issue = 2 | pages = 115–23 | date = April 2010 | pmid = 20350658 | pmc = 2848172 | doi = 10.1053/j.seminhematol.2010.01.011 }}</ref>

== 细胞因子疗法 ==
[[细胞因子|细胞因子]]是肿瘤内多种细胞产生的蛋白质，可用于调节免疫应答。而肿瘤则会设法利用细胞因子以促进自身生长，降低免疫应答。细胞因子所具有免疫调节功能使它们可以作为药物被用于激发免疫应答。[[干扰素|干扰素]]与[[白细胞介素|白细胞介素]]是两类最常用的细胞因子。<ref name="pmid14708024">{{cite journal | vauthors = Dranoff G | title = Cytokines in cancer pathogenesis and cancer therapy | journal = Nature Reviews. Cancer | volume = 4 | issue = 1 | pages = 11–22 | date = January 2004 | pmid = 14708024 | doi = 10.1038/nrc1252 }}</ref>

[[白细胞介素|白细胞介素]]-2（IL-2）与干扰素-α（IFNα）是能够调整、控制免疫系统行为的细胞因子。它们能增强抗肿瘤反应，因而被用于被动癌症治疗。干扰素-α被用于治疗{{le|毛细胞白血病|Hairy cell leukemia}}、与[[艾滋病|艾滋病]]有关的[[卡波西氏肉瘤|卡波西氏肉瘤]]、{{le|滤泡淋巴瘤|Follicular lymphoma}}、[[慢性粒细胞性白血病|慢性粒细胞性白血病]]与黑色素瘤。白细胞介素-2则被用于治疗黑色素瘤与肾细胞癌。

=== 干扰素 ===
干扰素（IFN）由免疫系统合成，一般与抗病毒应答有关，但亦可用于癌症。干扰素可分为I型（IFNα与IFNβ）、II型（IFNγ）与III型（IFNλ）三大家族。IFNα被批准用于治疗毛细胞白血病、与艾滋病有关的卡波西氏肉瘤、滤泡淋巴瘤、慢性粒细胞性白血病与黑色素瘤。I型与II型干扰素家族已被广泛研究，尽管有研究表明两者都能够提升免疫系统的抗肿瘤效果，但其中只有I型干扰素的效果经临床试验证实。IFNλ则在动物实验中表现出了抗肿瘤效应。<ref>{{cite journal | vauthors = Dunn GP, Koebel CM, Schreiber RD | title = Interferons, immunity and cancer immunoediting | journal = Nature Reviews. Immunology | volume = 6 | issue = 11 | pages = 836–48 | date = November 2006 | pmid = 17063185 | doi = 10.1038/nri1961 }}</ref><ref>{{cite journal | vauthors = Lasfar A, Abushahba W, Balan M, Cohen-Solal KA | title = Interferon lambda: a new sword in cancer immunotherapy | journal = Clinical & Developmental Immunology | volume = 2011 | pages = 349575 | year = 2011 | pmid = 22190970 | pmc = 3235441 | doi = 10.1155/2011/349575 }}</ref>

与I型干扰素不同，[[干扰素伽玛|IFNγ]]尚未被批准用于癌症治疗。不过，已有实验表明使用了IFNγ的[[膀胱癌|膀胱癌]]与黑色素瘤患者的生存率得到了提升。而在二期与三期[[卵巢癌|卵巢癌]]患者中，IFNγ的效果最为明显。肿瘤细胞中IFNγ的体外实验研究则更为充分，结果表明IFNγ能有效抑制肿瘤细胞的增殖，引发细胞凋亡或[[自噬|自噬]]机制最终杀死肿瘤细胞。<ref>{{cite journal | vauthors = Razaghi A, Owens L, Heimann K | title = Review of the recombinant human interferon gamma as an immunotherapeutic: Impacts of production platforms and glycosylation | journal = Journal of Biotechnology | volume = 240 | pages = 48–60 | date = December 2016 | pmid = 27794496 | doi = 10.1016/j.jbiotec.2016.10.022 }}</ref>

=== 白细胞介素 ===
白细胞介素（IL）有一系列免疫调节作用。IL-2被用于治疗黑色素瘤与肾细胞癌。一般情况下IL-2能够同时激活效应T细胞与调节T细胞，对其具体的作用机理尚待研究。<ref name="pmid14708024" /><ref>{{cite journal | vauthors = Coventry BJ, Ashdown ML | title = The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses | journal = Cancer Management and Research | volume = 4 | pages = 215–21 | year = 2012 | pmid = 22904643 | pmc = 3421468 | doi = 10.2147/cmar.s33979 }}</ref>

== 联合免疫疗法 ==
将多种免疫疗法合用（如同时使用PD-1与CTLA-4抑制剂）能够强化坑肿瘤应答，以达到持久应答的目的。<ref>{{cite journal | vauthors = Ott PA, Hodi FS, Kaufman HL, Wigginton JM, Wolchok JD | title = Combination immunotherapy: a road map | journal = Journal for Immunotherapy of Cancer | volume = 5 | pages = 16 | year = 2017 | pmid = 28239469 | pmc = 5319100 | doi = 10.1186/s40425-017-0218-5 }}</ref><ref>{{cite journal | vauthors = Mahoney KM, Rennert PD, Freeman GJ | title = Combination cancer immunotherapy and new immunomodulatory targets | journal = Nature Reviews. Drug Discovery | volume = 14 | issue = 8 | pages = 561–84 | date = August 2015 | pmid = 26228759 | doi = 10.1038/nrd4591 }}</ref>

冷冻消融联合免疫疗法则能够增强免疫刺激应答并产生协同效应，可用于以根治为目的转移性癌症治疗。<ref name="hindawi9251375">{{Cite journal|title=Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response?|year=2015|url=https://www.hindawi.com/journals/grp/2016/9251375/|journal=|author=|access-date=2018-10-04|archive-url=https://web.archive.org/web/20180602232433/https://www.hindawi.com/journals/grp/2016/9251375/|archive-date=2018-06-02|dead-url=no}}</ref>

在采用免疫检查点疗法的同时联用其他药物或许能加强免疫应答，这是目前临床研究的热点<ref>{{cite journal | vauthors = Tang J, Shalabi A, Hubbard-Lucey VM | title = Comprehensive analysis of the clinical immuno-oncology landscape | journal = Annals of Oncology | volume = 29 | issue = 1 | pages = 84–91 | date = January 2018 | pmid = 29228097 | doi = 10.1093/annonc/mdx755 }}</ref>，如联合使用{{le|CSF-1R|Colony stimulating factor 1 receptor}}抑制剂与[[Toll样受体|TLR]]激动剂就获得了良好效果。<ref>{{cite journal | vauthors = Perry CJ, Muñoz-Rojas AR, Meeth KM, Kellman LN, Amezquita RA, Thakral D, Du VY, Wang JX, Damsky W, Kuhlmann AL, Sher JW, Bosenberg M, Miller-Jensen K, Kaech SM | title = Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity | journal = The Journal of Experimental Medicine | volume = 215 | issue = 3 | pages = 877–893 | date = March 2018 | pmid = 29436395 | doi = 10.1084/jem.20171435 }}</ref><ref>{{cite journal| vauthors = Rodell CB, Arlauckas SP, Cuccarese MF, Garris CS, Li R, Ahmed MS, Kohler RH, Pittet MJ, Weissleder R |date=2018-05-21|title=TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy |journal=Nature Biomedical Engineering |doi=10.1038/s41551-018-0236-8 }}</ref>

== 多糖K ==
日本[[厚生劳动省|厚生劳动省]]于1980年代批准使用从[[云芝|云芝]]中提取的{{le|多糖K|Polysaccharide-K}}，用于激发化疗患者的免疫系统。但在美国等其他国家，多糖K属于[[膳食补充剂|膳食补充剂]]而非药物。<ref name="CoriolusVersicolor">{{cite web |archive-url=https://web.archive.org/web/20060215064239/http://www.cancer.org/docroot/ETO/content/ETO_5_3X_Coriolous_Versicolor.asp|url=http://www.cancer.org/docroot/ETO/content/ETO_5_3X_Coriolous_Versicolor.asp|archive-date=2006-02-15|dead-url=yes|title=Coriolus Versicolor|date=|publisher=American Cancer Society}}</ref>

== 研究 ==
=== 过继性T细胞疗法 ===
[[File:Adoptive_T-cell_therapy.png|thumb]]

过继性T细胞疗法（adoptive T-cell therapy）是一种向患者输送T细胞的被动免疫疗法。T细胞存在于血液与组织内，通常在有外源[[病原体|病原体]]时会激活。当T细胞的表面受体遇到表面抗原上呈现出外源蛋白质的细胞时，T细胞会被激活。这些细胞可以是被感染细胞或者[[抗原提呈细胞|抗原提呈细胞]]（APC）。T细胞同时出现在正常组织与肿瘤组织中，在肿瘤组织中的T细胞被称为{{le|肿瘤浸润淋巴细胞|Tumor-infiltrating lymphocytes}}（TIL）。DC细胞等APC将肿瘤抗原提呈给T细胞后能将T细胞激活。尽管被激活的T细胞有能力攻击肿瘤，但由于肿瘤所在的环境能够抑制免疫反应，从而防止了免疫介导的肿瘤杀伤机制。<ref name="NatureRev2012">{{cite journal | vauthors = Restifo NP, Dudley ME, Rosenberg SA | title = Adoptive immunotherapy for cancer: harnessing the T cell response | journal = Nature Reviews. Immunology | volume = 12 | issue = 4 | pages = 269–81 | date = March 2012 | pmid = 22437939 | doi = 10.1038/nri3191 }}</ref>

有多种方法能够生成靶向肿瘤的T细胞。肿瘤样本或者血液中能够分离出肿瘤抗原特异性的T细胞，之后再在体外培养并激活这些T细胞，激活手段包括基因治疗或者将T细胞暴露于肿瘤抗原之中。

目前，已有多项以{{le|过继性细胞输注|Adoptive cell transfer}}（ACT）为基础的临床试验。<ref>{{cite web|first=John|last=Carroll|name-list-format=vanc|work=Fierce Biotech|date=December 2013|url=http://www.fiercebiotech.com/story/novartispenns-customized-t-cell-wows-ash-stellar-leukemia-data/2013-12-09|title=Novartis/Penn's customized T cell wows ASH with stellar leukemia data|access-date=2018-10-04|archive-url=https://web.archive.org/web/20160304063331/http://www.fiercebiotech.com/story/novartispenns-customized-t-cell-wows-ash-stellar-leukemia-data/2013-12-09|archive-date=2016-03-04|dead-url=no}}</ref><ref>{{cite web|first=John|last=Carroll|work=FierceBiotech|date=February 2014|url=http://www.fiercebiotech.com/story/servier-stages-entry-high-stakes-car-t-showdown-novartis/2014-02-18|title=Servier stages an entry into high-stakes CAR-T showdown with Novartis|access-date=2018-10-04|archive-url=https://web.archive.org/web/20160303233448/http://www.fiercebiotech.com/story/servier-stages-entry-high-stakes-car-t-showdown-novartis/2014-02-18|archive-date=2016-03-03|dead-url=no}}</ref><ref>{{cite web | title = Biotech’s Coming Cancer Cure: Supercharge your immune cells to defeat cancer? Juno Therapeutics believes its treatments can do exactly that| url=http://www.technologyreview.com/featuredstory/538441/biotechs-coming-cancer-cure/|first=Antonio|last=Regalado|name-list-format=vanc|date=June 2015|work=[[MIT_Technology_Review|MIT Technology Review]]}}</ref><ref>{{cite web|url=http://www.cancer.gov/cancertopics/research-updates/2013/CAR-T-Cells|title=CAR T-Cell Therapy: Engineering Patients’ Immune Cells to Treat Their Cancers|publisher=cancer.gov|date=2013-12-06|accessdate=2014-05-09|archive-url=https://web.archive.org/web/20140512214921/http://www.cancer.gov/cancertopics/research-updates/2013/CAR-T-Cells|archive-date=2014-05-12|dead-url=no}}</ref><ref>{{cite web|url=http://www.nih.gov/news/health/may2014/nci-08.htm|title=NIH study demonstrates that a new cancer immunotherapy method could be effective against a wide range of cancers|publisher=nih.gov|date=2014-05-08|accessdate=2014-05-09|archive-url=https://web.archive.org/web/20140509010803/http://www.nih.gov/news/health/may2014/nci-08.htm|archive-date=2014-05-09|dead-url=no}}</ref>2018年发表的一项研究表明，此前多种免疫疗法治疗无效的转移性黑色素瘤患者在经ACT治疗后表现出了临床疗效。<ref name="pmid29688262">{{cite journal |vauthors=Andersen R, Borch TH, Draghi A, Gokuldass A, Rana MA, Pedersen M, Nielsen M, Kongsted P, Kjeldsen JW, Westergaard MC, Radic HD, Chamberlain CA, Holmich LR, Hendel HW, Larsen MS, Met O, Svane IM, Donia M | title = T cells isolated from patients with checkpoint inhibitor resistant-melanoma are functional and can mediate tumor regression. | journal = Ann. Oncol. | date=April 2018 | pmid = 29688262 | doi = 10.1093/annonc/mdy139 }}</ref>

2017年，FDA首次批准了{{le|tisagenlecleucel}}与{{le|axicabtagene ciloleucel}}两个过继性T细胞疗法。<ref>{{cite web|url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm|title=FDA approval brings first gene therapy to the United States|publisher=fda.gov|date=2017-08-30|accessdate=2017-11-08|archive-url=https://web.archive.org/web/20170903080825/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm|archive-date=2017-09-03|dead-url=no}}</ref><ref name="fda.gov"/>

此外，另一种方法是采用健康异体供者的半相合{{le|γδ T细胞|Gamma delta T cell}}或NK细胞进行过继性输注。此方法不会造成[[移植物对抗宿主疾病|移植物对抗宿主疾病]]（GvHD），但被移植细胞的功能常会出现受损情形。<ref name="pmid = 24528541">{{cite journal | vauthors = Wilhelm M, Smetak M, Schaefer-Eckart K, Kimmel B, Birkmann J, Einsele H, Kunzmann V | title = Successful adoptive transfer and in vivo expansion of haploidentical γδ T cells | journal = Journal of Translational Medicine | volume = 12 | issue =  | pages = 45 | date = February 2014 | pmid = 24528541 | pmc = 3926263 | doi = 10.1186/1479-5876-12-45 }}</ref>

=== 抗CD47疗法 ===
许多肿瘤细胞上存在{{le|CD47|}}过表达的现象，从而逃避宿主免疫系统的监视。CD47与其受体{{le|信号调节蛋白α|Signal-regulatory protein alpha}}（SIRPα）的结合，使肿瘤细胞得以逃避巨噬细胞对其的[[吞噬作用|吞噬]]。<ref>{{cite journal | vauthors = Jaiswal S, Chao MP, Majeti R, Weissman IL | title = Macrophages as mediators of tumor immunosurveillance | journal = Trends in Immunology | volume = 31 | issue = 6 | pages = 212–9 | date = June 2010 | pmid = 20452821 | doi = 10.1016/j.it.2010.04.001 | pmc = 3646798 }}</ref>抗CD47疗法的目的即是恢复吞噬作用。现在已有证据表明抗CD47疗法能够引发T细胞对肿瘤的特异性杀伤作用。<ref name=":1">{{cite journal | vauthors = Weiskopf K | title = Cancer immunotherapy targeting the CD47/SIRPα axis | journal = European Journal of Cancer | volume = 76 | pages = 100–109 | date = May 2017 | pmid = 28286286 | doi = 10.1016/j.ejca.2017.02.013 }}</ref><ref>{{cite journal | vauthors = Matlung HL, Szilagyi K, Barclay NA, van den Berg TK | title = The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer | journal = Immunological Reviews | volume = 276 | issue = 1 | pages = 145–164 | date = March 2017 | pmid = 28258703 | doi = 10.1111/imr.12527 }}</ref>多项以此为基础的疗法正在研发之中，其中包括抗CD47抗体、{{le|诱骗受体|Decoy receptors}}、抗SIRPα抗体、双特异性抗体等。<ref name=":1" />截至2017年，多项针对实体肿瘤与血液系统肿瘤的临床试验已经启动。<ref name=":1" /><ref>{{cite journal | vauthors = Veillette A, Chen J | title = SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy | journal = Trends in Immunology | volume = 39 | issue = 3 | pages = 173–184 | date = March 2018 | pmid = 29336991 | doi = 10.1016/j.it.2017.12.005 }}</ref>

=== 抗GD2疗法 ===
[[File:GD2_ganglioside.png|thumb]]
细胞表面的糖类抗原可以作为免疫疗法的靶点。{{le|GD2}}是一种[[神经节苷脂|神经节苷脂]]，存在于多种肿瘤细胞表面，包括{{le|神经母细胞瘤|Neuroblastoma}}、[[视网膜母细胞瘤|视网膜母细胞瘤]]、黑色素瘤、[[小细胞肺癌|小细胞肺癌]]、[[脑瘤|脑瘤]]、{{le|骨肉瘤|Osteosarcoma}}、[[横纹肌肉瘤|横纹肌肉瘤]]、[[尤文氏肉瘤|尤文氏肉瘤]]、[[脂肪肉瘤|脂肪肉瘤]]、{{le|纤维肉瘤|Fibrosarcoma}}、[[平滑肌肉瘤|平滑肌肉瘤]]以及其他{{le|软组织肉瘤|Soft-tissue sarcoma}}。由于正常组织表面一般不会表达GD2，使其成为免疫疗法的一个潜在靶点。目前已有相关临床试验在进行中。<ref>{{cite journal | vauthors = Ahmed M, Cheung NK | title = Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy | journal = FEBS Letters | volume = 588 | issue = 2 | pages = 288–97 | date = January 2014 | pmid = 24295643 | doi = 10.1016/j.febslet.2013.11.030 }}</ref>

=== 免疫检查点 ===
[[File:11_Hegasy_CTLA4_PD1_Immunotherapy.png|left]]
{{le|免疫检查点|Immune checkpoint}}能够影响免疫系统的功能，其可以是刺激性或抑制性的。肿瘤会利用这些检查点来保护自己、逃避免疫系统的攻击。目前经批准的免疫检查点疗法皆是通过阻断抑制性检查点受体发挥作用的。当负反馈信号被阻断后能够激起机体的免疫应答以杀伤肿瘤。<ref name="pmid22437870">{{cite journal | vauthors = Pardoll DM | title = The blockade of immune checkpoints in cancer immunotherapy | journal = Nature Reviews. Cancer | volume = 12 | issue = 4 | pages = 252–64 | date = March 2012 | pmid = 22437870 | pmc = 4856023 | doi = 10.1038/nrc3239 }}</ref>

跨膜蛋白{{le|细胞程序性死亡受体1|Programmed cell death protein 1}}（PD-1，又称CD279）与其配体[[细胞程序性死亡配体1|细胞程序性死亡配体1]]（PD-L1，又称CD274）间的相互作用是一个研究热点。肿瘤细胞表面的PD-L1能够与免疫细胞表面的PD-1相结合，以维护免疫抑制环境。PD-L1能调节T细胞功能，肿瘤通过上调PD-L1表达来抑制T细胞的活化。此外，PD-L1还能抑制依赖FAS与干扰素的细胞凋亡过程，从而保护肿瘤细胞免受由T细胞生成的细胞毒分子的杀伤。能够与PD-1或PD-L1结合的抗体可用于阻断它们的相互作用，以使T细胞发挥功能、攻击肿瘤。<ref name="ReferenceA">{{cite journal | vauthors = Granier C, De Guillebon E, Blanc C, Roussel H, Badoual C, Colin E, Saldmann A, Gey A, Oudard S, Tartour E | title = Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer | journal = ESMO Open | volume = 2 | issue = 2 | pages = e000213 | date = 2017 | pmid = 28761757 | pmc = 5518304 | doi = 10.1136/esmoopen-2017-000213 }}</ref>

==== CTLA-4抑制剂 ====
2011年，FDA批准了首个免疫检查点抗体——用于治疗黑色素瘤的伊匹单抗。<ref>{{cite journal | vauthors = Cameron F, Whiteside G, Perry C | title = Ipilimumab: first global approval | journal = Drugs | volume = 71 | issue = 8 | pages = 1093–104 | date = May 2011 | pmid = 21668044 | doi = 10.2165/11594010-000000000-00000 }}</ref>伊匹单抗能够阻断检查点分子{{le|细胞毒性T淋巴细胞相关抗原4|CTLA-4}}（CTLA-4）。而临床试验还表明抗CTLA-4疗法有利于肺癌与胰腺癌治疗，并能通过联合用药增强疗效。<ref>{{cite journal | vauthors = Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H, Cuillerot JM, Reck M | title = Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study | journal = Journal of Clinical Oncology | volume = 30 | issue = 17 | pages = 2046–54 | date = June 2012 | pmid = 22547592 | doi = 10.1200/JCO.2011.38.4032 }}</ref><ref>{{cite journal | vauthors = Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, Zheng L, Diaz LA, Donehower RC, Jaffee EM, Laheru DA | title = Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer | journal = Journal of Immunotherapy | volume = 36 | issue = 7 | pages = 382–9 | date = September 2013 | pmid = 23924790 | pmc = 3779664 | doi = 10.1097/CJI.0b013e31829fb7a2 }}</ref>目前有试验正研究多种类型的癌症治疗中联用CTLA-4抑制剂与PD-1/PD-L1抑制剂的效果。<ref>{{ClinicalTrialsGov|NCT01928394|A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors}}</ref>

不过，使用检查点抗体（尤其是CTLA-4抗体）的患者常饱受免疫介导的不良反应困扰，这些副作用主要影响皮肤、胃肠道、肝脏与内分泌系统。<ref>{{cite journal | vauthors = Postow MA, Callahan MK, Wolchok JD | title = Immune Checkpoint Blockade in Cancer Therapy | journal = Journal of Clinical Oncology | volume = 33 | issue = 17 | pages = 1974–82 | date = June 2015 | pmid = 25605845 | pmc = 4980573 | doi = 10.1200/JCO.2014.59.4358 }}</ref>这可能是由于注入的抗体在血液中扩散，进而在大范围内激活了T细胞。

科研人员利用小鼠膀胱癌模型研究发现，在肿瘤区域局域低剂量注入CTLA-4抗体时取得的肿瘤抑制效果与将抗体输送至全身的效果相当。<ref name=":3">{{cite journal | vauthors = van Hooren L, Sandin LC, Moskalev I, Ellmark P, Dimberg A, Black P, Tötterman TH, Mangsbo SM | title = Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer | journal = European Journal of Immunology | volume = 47 | issue = 2 | pages = 385–393 | date = February 2017 | pmid = 27873300 | doi = 10.1002/eji.201646583 }}</ref>由于局域输入抗体能够减少其扩散，该疗法可能有助于降低治疗的副作用。<ref name=":3" />

==== PD-1抑制剂 ====
抗PD-1的IgG4纳武单抗的试验结果于2010年首次发表<ref name="pmid22437870" />，2014年被批准。纳武单抗可用于治疗黑色素瘤、肺癌、肾癌、膀胱癌、头颈癌、[[霍奇金淋巴瘤|霍奇金淋巴瘤]]等。<ref name=":2">{{Cite news|url=https://www.nytimes.com/2016/05/19/business/food-and-drug-administration-immunotherapy-bladder-cancer.html|title=F.D.A. Approves an Immunotherapy Drug for Bladder Cancer|access-date=2016-05-21|last=Pollack|first=Andrew|name-list-format=vanc|date=2016-05-18|newspaper=The New York Times|issn=0362-4331|archive-url=https://web.archive.org/web/20160521193332/http://www.nytimes.com/2016/05/19/business/food-and-drug-administration-immunotherapy-bladder-cancer.html|archive-date=2016-05-21|dead-url=no}}</ref>2016年的一项针对非小细胞肺癌的纳武单抗临床试验并没能达到一线治疗的主要终点目标，但FDA批准其可用于二、三线治疗。<ref>{{Cite news|url=https://www.wsj.com/articles/bristol-myers-opdivo-failed-to-meet-endpoint-in-key-lung-cancer-study-1470400926|title=Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung-Cancer Study|last=Steele|first=Anne|name-list-format=vanc|date=2016-08-05|newspaper=Wall Street Journal|issn=0099-9660|access-date=2016-08-05|archive-url=https://web.archive.org/web/20160806121143/http://www.wsj.com/articles/bristol-myers-opdivo-failed-to-meet-endpoint-in-key-lung-cancer-study-1470400926|archive-date=2016-08-06|dead-url=no}}</ref>

帕姆单抗是另一种PD-1抑制剂，于2014年被FDA批准用于治疗黑色素瘤与肺癌。<ref name=":2" />

{{le|替雷利珠单抗|Tislelizumab}}（tislelizumab，BGB-A317）则消除了与Fcγ受体的结合能力，目前处于早期临床试验阶段。<ref>{{cite web|url=https://globenewswire.com/news-release/2016/06/05/846118/0/en/BeiGene-Presents-Initial-Clinical-Data-on-PD-1-Antibody-BGB-A317-at-the-2016-American-Society-of-Clinical-Oncology-Annual-Meeting.html|title=BeiGene Presents Initial Clinical Data on PD-1 Antibody BGB-A317 at the 2016 American Society of Clinical Oncology Annual Meeting|author=BeiGene, Ltd.|publisher=Globe Newswire|access-date=2018-10-04|archive-url=https://web.archive.org/web/20170824215902/http://globenewswire.com/news-release/2016/06/05/846118/0/en/BeiGene-Presents-Initial-Clinical-Data-on-PD-1-Antibody-BGB-A317-at-the-2016-American-Society-of-Clinical-Oncology-Annual-Meeting.html|archive-date=2017-08-24|dead-url=no}}</ref>

==== PD-L1抑制剂 ====
2016年，PD-L1抑制剂阿特珠单抗被批准用于治疗膀胱癌。<ref>{{cite web|url=http://www.roche.com/investors/updates/inv-update-2016-04-11.htm|title=FDA grants priority review for Roche's cancer immunotherapy atezolizumab in specific type of lung cancer|last1=Roche|access-date=2018-10-04|archive-url=https://web.archive.org/web/20170908195231/http://www.roche.com/investors/updates/inv-update-2016-04-11.htm|archive-date=2017-09-08|dead-url=no}}</ref>

目前其他正在研发中的PD-L1抗体包括{{le|阿维单抗|Avelumab}}<ref>{{cite web|last1=Merck Group|title=Immuno-oncology Avelumab|url=http://www.merckgroup.com/en/innovation/research_activities/immuno_oncology/immuno_oncology.html|access-date=2018-10-04|archive-url=https://web.archive.org/web/20170611174753/http://www.merckgroup.com/en/innovation/research_activities/immuno_oncology/immuno_oncology.html|archive-date=2017-06-11|dead-url=no}}</ref>、度伐鲁单抗<ref>{{cite web|last1=Cure today|title=Durvalumab continues to progress in treatment of advanced bladder cancer.|url=http://www.curetoday.com/articles/durvalumab-continues-to-progress-in-treatment-of-advanced-bladder-cancer|access-date=2018-10-04|archive-url=https://web.archive.org/web/20170817033831/http://www.curetoday.com/articles/durvalumab-continues-to-progress-in-treatment-of-advanced-bladder-cancer|archive-date=2017-08-17|dead-url=no}}</ref>以及一种名为{{le|Affimer}}的抗体替代技术。<ref>{{cite web|last1=Avacta Life Sciences|title=Affimer biotherapeutics target cancer's off-switch with PD-L1 inhibitor|url=https://www.avactalifesciences.com/blogs/affimer-biotherapeutics-target-cancer-s-switch-pd-l1-inhibitor|access-date=2018-10-04|archive-url=https://web.archive.org/web/20160806162015/https://www.avactalifesciences.com/blogs/affimer-biotherapeutics-target-cancer-s-switch-pd-l1-inhibitor|archive-date=2016-08-06|dead-url=no}}</ref>

==== 其他 ====
其他方法还包括以细胞内免疫检查点（如{{le|CISH}}）为靶点的检查点阻断疗法。还有些癌症患者经免疫检查点阻断治疗后没有缓解。与其他癌症疗法联用或许能提高检查点阻断疗法的缓解率。对癌症动物模型的研究表明，联合放疗、血管靶向药物以及免疫原性化疗（immunogenic chemotherapy）<ref>{{cite journal | vauthors = Pfirschke C, Engblom C, Rickelt S, Cortez-Retamozo V, Garris C, Pucci F, Yamazaki T, Poirier-Colame V, Newton A, Redouane Y, Lin YJ, Wojtkiewicz G, Iwamoto Y, Mino-Kenudson M, Huynh TG, Hynes RO, Freeman GJ, Kroemer G, Zitvogel L, Weissleder R, Pittet MJ | display-authors = 6 | title = Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy | journal = Immunity | volume = 44 | issue = 2 | pages = 343–54 | date = February 2016 | pmid = 26872698 | doi = 10.1016/j.immuni.2015.11.024 }}</ref>等能提升检查点阻断的疗效。

=== 溶瘤病毒 ===
{{le|溶瘤病毒|Oncolytic virus}}是一类能感染并杀伤肿瘤细胞的病毒。溶瘤病毒可以特异性地在肿瘤细胞中复制、增殖，并释放出新的感染性病毒颗粒破坏其他肿瘤细胞。这种病毒不仅能直接杀死肿瘤细胞，还能刺激宿主的抗肿瘤免疫应答以利于长期免疫治疗。<ref name=pmid27486853>{{cite journal | vauthors = Fukuhara H, Ino Y, Todo T | title = Oncolytic virus therapy: A new era of cancer treatment at dawn | journal = Cancer Science | volume = 107 | issue = 10 | pages = 1373–1379 | date = October 2016 | pmid = 27486853 | pmc = 5084676 | doi = 10.1111/cas.13027 }}</ref><ref name=pmid28589082>{{cite journal | vauthors = Haddad D | title = Genetically Engineered Vaccinia Viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery | journal = Frontiers in Oncology | volume = 7 | pages = 96 | year = 2017 | pmid = 28589082 | pmc = 5440573 | doi = 10.3389/fonc.2017.00096 }}</ref><ref name=pmid29329556>{{cite journal | vauthors = Marin-Acevedo JA, Soyano AE, Dholaria B, Knutson KL, Lou Y | title = Cancer immunotherapy beyond immune checkpoint inhibitors | journal = Journal of Hematology & Oncology | volume = 11 | issue = 1 | pages = 8 | date = January 2018 | pmid = 29329556 | pmc = 5767051 | doi = 10.1186/s13045-017-0552-6 }}</ref>

利用病毒来治疗癌症的想法早在20世纪初便已出现，不过直至1960年代后该领域的研究才开始逐渐系统化。[[腺病毒|腺病毒]]、[[呼肠孤病毒|呼肠孤病毒]]、[[麻疹病毒|麻疹病毒]]、[[单纯疱疹病毒|单纯疱疹病毒]]、[[新城病|新城病]]病毒、[[牛痘病毒|牛痘病毒]]等都先后在临床试验中被用作溶瘤病毒。{{le|T-Vec|Talimogene laherparepvec}}则是首个经FDA批准的溶瘤病毒，可用于治疗黑色素瘤。另有其他多种溶瘤病毒正经历二期、三期临床试验。

=== 多糖 ===
在[[蕈类|蕈类]]中发现的[[多糖|多糖]]等化合物可用于调节免疫系统，或有助于癌症治疗。例如，有实验研究发现{{le|β-葡聚糖|Beta-glucan}}（如[[香菇多糖|香菇多糖]]）可激活巨噬细胞、NK细胞、T细胞及免疫系统细胞因子，已有临床试验研究其作为[[免疫佐剂|免疫佐剂]]的效果。<ref>{{cite journal | vauthors = Aleem E | title = β-Glucans and their applications in cancer therapy: focus on human studies | journal = Anti-Cancer Agents in Medicinal Chemistry | volume = 13 | issue = 5 | pages = 709–19 | date = June 2013 | pmid = 23140353 | doi = 10.2174/1871520611313050007 }}</ref>

=== 新生抗原 ===
许多肿瘤细胞会出现基因突变，而这些突变可作为T细胞免疫治疗潜在的靶抗原，这些抗原就被称为“新生抗原”（neoantigen）。RNA测序数据表明，突变负荷（mutational burdern）越高的肿瘤中CD8+T细胞越多。NK细胞与T细胞的细胞杀伤活性与许多肿瘤的突变负荷呈正相关。在接受帕姆单抗治疗的非小细胞肺癌患者中，突变负荷与疗效显著相关。而在接受伊匹单抗治疗的黑色素瘤患者中，治疗的长期效果亦与突变负荷相关，尽管程度不及前例。有研究分析了经MHC呈递的新生抗原肽段后发现，治疗效果好的患者的肽段中有一组{{le|四肽|Tetrapeptide}}序列，而在治疗无效或低效的患者中却没有。<ref name="SnyderMakarov2014">{{cite journal | vauthors = Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, Hollmann TJ, Bruggeman C, Kannan K, Li Y, Elipenahli C, Liu C, Harbison CT, Wang L, Ribas A, Wolchok JD, Chan TA | title = Genetic basis for clinical response to CTLA-4 blockade in melanoma | journal = The New England Journal of Medicine | volume = 371 | issue = 23 | pages = 2189–2199 | date = December 2014 | pmid = 25409260 | pmc = 4315319 | doi = 10.1056/NEJMoa1406498 }}</ref>不过其他一些研究中的新生抗原却没有表现出四肽特征。<ref name="ss15">{{cite journal | vauthors = Schumacher TN, Schreiber RD | title = Neoantigens in cancer immunotherapy | journal = Science | volume = 348 | issue = 6230 | pages = 69–74 | date = April 2015 | pmid = 25838375 | doi = 10.1126/science.aaa4971 | bibcode = 2015Sci...348...69S }}</ref>

== 参见 ==
* [[癌症疫苗|癌症疫苗]]

== 参考文献 ==
{{reflist|3}}
{{Extracellular chemotherapeutic agents}}
[[Category:癌症治疗|Category:癌症治疗]]
[[Category:免疫学|Category:免疫学]]